Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Suozzi, Kathleen C.; Stahl, Maximilian; Ko, Christine J.; Chiang, Anne C.; Gettinger, Scott; Siegel, Mark D.; Bunick, Christopher G.

doi:10.1016/j.jdcr.2016.05.002

Cited by 93 publications

(63 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is approved by the US Food and Drug Administration for the treatment of metastatic melanoma, non–small cell lung cancer, renal cell carcinoma, and classical Hodgkin lymphoma 1 . Immune-related adverse events (irAEs), such as colitis, endocrinopathies, and dermatitis, have been well documented in patients treated with checkpoint inhibitors 3 . We report a case of immune-related cutaneous sarcoidosis in a patient with lung adenocarcinoma on nivolumab monotherapy.…”

Section: Introductionmentioning

confidence: 96%

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 96%

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

et al. 2017

View full text Add to dashboard Cite

“…Patients present commonly with nonspecific morbilliform eruptions, but alternate clinical presentations reported with anti-PD-1/PD-L1 include psoriasis, 7–11 bullous pemphigoid (BP), 12–16 sarcoidosis, 17–19 and Stevens Johnson syndrome/toxic epidermal necrolysis. 20 For a detailed, comprehensive review of the broad array of presentations published to date, see Curry, et al 2016.…”

Section: Introductionmentioning

confidence: 99%

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade

Kaunitz¹,

Loss²,

Rizvi³

et al. 2017

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Cutaneous eruptions are among the most common immune-related adverse events (irAEs) associated with anti-PD-1/PD-L1 therapy, and are often clinically and histologically characterized as lichenoid. Non-lichenoid patterns may also occur and are likely to be encountered by surgical pathologists, given the increasing clinical use of these agents. The purpose of this study is to describe the histopathologic features of non-lichenoid cutaneous irAEs from patients receiving anti-PD-1/PD-L1 therapies for a variety of underlying advanced malignancies. Sixteen patients with 17 biopsied eruptions were included from two academic institutions with extensive experience administering and monitoring responses to immune checkpoint blockade as well as treating the potential side effects. Eruptions occurred a median of 10 days (range 1 day to 11.4 months) after treatment initiation. Nearly half of specimens demonstrated either a psoriasiform/spongiotic or an urticarial-type reaction pattern on histologic review. Patterns consistent with Grover’s disease, bullous pemphigoid, and granulomatous dermatitis were also observed. Nearly two-thirds of patients required systemic corticosteroids for treatment of the cutaneous irAE, and 19% of patients discontinued immunotherapy due to their skin eruptions. 75% of patients showed an objective antitumor response. The diverse array of non-lichenoid cutaneous irAE presented here should reflect and inform the scope of histologic patterns encountered by the practicing surgical pathologist. Such eruptions are seen in patients with a variety of underlying tumor types, many of whom ultimately demonstrate a favorable response to immune checkpoint blockade.

show abstract

“…PD-1 inhibitors are known to cause thyroid hypofunction by causing primary thyroid failure (Uncanny resemblance to Hashimoto's thyroiditis). [4] Few cases of hyperthyroidism have also been reported. [5] …”

Section: Thyroid Diseasementioning

confidence: 99%

“…[3] Lymphadenopathy appearing in the middle of a cancer treatment usually leads to conclusions of cancer progression and treatment failure, but a sarcoid-like syndrome with significant adenopathy has been described. [4] Although rare (11 cases), it is probably underdiagnosed. Immune lymphocytic myocarditis is increasingly being reported as are arthritis and pancreatitis.…”

Section: Miscellaneousmentioning

confidence: 99%

Unforeseen consequences of cancer immunotherapy

Vaishnav¹,

Arslan²,

Mehta³

2018

Int J Mol Immuno Oncol.

View full text Add to dashboard Cite

<p>With the increasing use of immunotherapy for various cancers, it is essential that clinicians become aware of some of the unique consequences and sude effects associated with these new treatments. Ranging from pneumonitis and colitis to Type 1 Diabetes Mellitus, immune related adverse events have been reported. Some side effects may be confused with cancer progression and thus awareness and clinical presentation of these is critical and necessary in this fast moving field of medicine.</p>

show abstract

Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy

Cited by 93 publications

References 18 publications

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma

Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade

Unforeseen consequences of cancer immunotherapy

Contact Info

Product

Resources

About